Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2021 08:00 ET | Source: Immutep Limited

Immutep Reveals a New Anti-LAG-3 Research Program

SYDNEY, AUSTRALIA, June 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for...
June 04, 2021 08:00 ET | Source: Immutep Limited

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

Encouraging activity signals from the combination of efti and avelumab with a response rate of 41.7% in different solid tumours (DCR 50%) acc. to RECIST 1.1No selection of patients for immunogenic...
June 04, 2021 08:00 ET | Source: Immutep Limited

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable overall response rate (ORR) together with favourable duration and depth of responses in 1st line NSCLC (41.7%,...
June 02, 2021 08:00 ET | Source: Immutep Limited

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
June 01, 2021 08:00 ET | Source: Immutep Limited

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

Collaboration with Merck KGaA, Darmstadt, Germany to evaluate eftilagimod alpha in combination with bintrafusp alfaNew investigator-initiated explorative, multi-centre, open-labelled Phase I/IIa trial...
May 26, 2021 08:00 ET | Source: Immutep Limited

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

SYDNEY, AUSTRALIA, May 26, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
May 25, 2021 08:00 ET | Source: Immutep Limited

Immutep To Present At The Jefferies Virtual Healthcare Conference

SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
May 20, 2021 08:00 ET | Source: Immutep Limited

Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

SYDNEY, AUSTRALIA, May 20, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
May 07, 2021 08:00 ET | Source: Immutep Limited

Immutep Operational Update

AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing wellNew data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021TACTI-003 clinical trial design enables evaluation...
April 28, 2021 10:21 ET | Source: Immutep Limited

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for...